0001104659-19-077377.txt : 20191231 0001104659-19-077377.hdr.sgml : 20191231 20191231180546 ACCESSION NUMBER: 0001104659-19-077377 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191227 FILED AS OF DATE: 20191231 DATE AS OF CHANGE: 20191231 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Versant Venture Capital VI, L.P. CENTRAL INDEX KEY: 0001687880 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 191320282 BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: (415) 801-8100 MAIL ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 170 HARBOR WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 170 HARBOR WAY CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 a4.xml 4 X0306 4 2019-12-27 0 0001744659 Akero Therapeutics, Inc. AKRO 0001687880 Versant Venture Capital VI, L.P. ONE SANSOME STREET, SUITE 3630 SAN FRANCISCO CA 94104 0 0 1 0 Common Stock 2019-12-27 4 S 0 33256 22.58 D 4012711 D Common Stock 2019-12-30 4 S 0 338919 24.39 D 3673792 D Common Stock 2019-12-31 4 S 0 17207 23.48 D 3656585 D The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan. These sales were executed in multiple trades at prices ranging from $21.56 to $23.52. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. These sales were executed in multiple trades at prices ranging from $22.98 to $33.61. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. These sales were executed in multiple trades at prices ranging from $[ ] to $[ ]. The price reported above reflects the weighted average sale price. The reporting persons hereby undertake to provide full information regarding the number of shares and prices at which these sales were effected, upon request, to the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer. These shares are owned directly by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, LP ("Versant GP LP") is the general partner of Versant VI and Versant Ventures VI GP-GP, LLC ("Versant GP LLC") is the general partner of Versant GP LP and the ultimate general partner of Versant VI. Versant GP LP and Versant GP LLC may be deemed to have voting and investment power over the securities held by Versant VI and as a result may be deemed to have beneficial ownership over such securities. VERSANT VENTURE CAPITAL VI, L.P.By: Versant Ventures VI GP, L.P., its general partner By: Versant Ventures VI GP-GP, LLC, its general partner By: /s/ Robin L. Praeger Robin L. Praeger, Managing Director 2019-12-31 Versant Ventures VI GP, L.P. By: Versant Ventures VI GP-GP, LLC, its general partner Its: General Partner By: /s/ Robin L. Praeger Robin L. Praeger, Managing Director 2019-12-31 Versant Ventures VI GP-GP, LLC By: /s/ Robin L. Praeger Robin L. Praeger, Managing Director 2019-12-31